Aim: To investigate the molecular mechanism and signaling pathway by which fenoterol, a β 2 -adrenergic receptor (β 2 -AR) agonist, produces anti-inflammatory effects. Methods: THP-1, a monocytic cell line, was used to explore the mechanism of β 2 -AR stimulation in LPS-induced secretion of inflammatory cytokines and changes of toll-like receptors (TLRs). We labeled TLR4 and CD14 using monoclonal anti-TLR4 PE-conjugated and anti-CD14 FITC-conjugated antibodies in THP-1 cells stimulated by β 2 -AR in the presence or absence of lipopolysaccharide (LPS) and small, interfering RNA (siRNA)-mediated knockdown of β-arrestin-2, and then analyzed their changes in distribution by flow cytometry, Western blotting and confocal analysis. Results: LPS-induced membrane-bound CD14, TLR4/CD14 complex levels and elevation of inflammatory cytokines were all significantly reduced by pre-incubation of fenoterol (P<0.05). However, the total level of CD14 and TLR4 was not significantly changed. Interestingly, confocal microscopy revealed redistribution of CD14 and TLR4/CD14 complex under β 2 -AR stimulation. Furthermore, siRNAmediated knockdown of β-arrestin-2 eliminated the anti-inflammatory effects and redistribution of CD14 and TLR4/CD14 complex stimulated by β 2 -AR. Conclusion: β 2 -AR agonist exerts its anti-inflammatory effects by down-regulating TLR signaling in THP-1 cells, potentially resulting from β-arrestin-2 mediated redistribution of CD14 and TLR14/CD14 complex.
Introduction β 2 -adrenergic receptor (β 2 -AR) agonist is administered in a variety of clinical situations [1] [2] [3] [4] [5] mostly for its bronchodilating effects. Furthermore, the regulation of β 2 -AR agonist on the production of inflammatory cytokines has been recognized. For example, it was shown that, salbutamol and albuterol, agonists of β 2 -AR, could inhibit tumor necrosis factor (TNF)-α production by human mononuclear cells [6, 7] , in addition, salbutamol exerts immunosuppressive effects through downregulation of co-stimulatory molecules, inter-cellular adhesion molecule 1 (ICAM-1), CD40 and CD14 on monocytes [7] , endocytosis of the TLR4 complex was pertinent to anti-inflammatory effects [8] . Whether β 2 -AR stimulation mediated antiinflammatory effects in monocytes depending on the endocytosis or redistribution of TLRs is not clear. Therefore, it is necessary to make clear the exact target of β 2 -AR stimulation during the process of anti-inflammation. Upon agonist binding, β-arrestins1/2 is recruited to the plasma membrane and interacts directly with two structural components of clathrin-coated pits, clathrin and AP-2, which promote the endocytosis of β 2 -AR into early endosomes via clathrin-coated vesicles [9] [10] . Moreover, TLR4 was also endocytosed by a dynamin and clathrin dependent mechanism and colocalized with lipopolysaccharide (LPS) on early sorting endosomes [11] . Therefore, we hypothesized that β 2 -AR stimulation mediated β-arrestins' translocation was associated with redistribution of TLRs.
Lipopolysaccharide (LPS)-induced inflammation in THP-1 cells is a model to study TLRs [12] . As a receptor of LPS, TLRs play an important role during LPS-induced inflammation [13] .
Fenoterol, a β 2 -adrenoceptor agonist, inhibits LPSinduced membrane-bound CD14, TLR4/CD14 complex, and inflammatory cytokines production through β-arrestin-2 in THP-1 cell line npg Recent studies have reported that β 2 -adrenergic agonist exert its "anti-inflammatory" effects in monocytic cells through the IκB/NF-κB pathway [6] . On the other hand, IκB/NF-κB is downstream signaling of TLR, which plays a pivotal role in regulating inflammatory gene expression and LPS-induced inflammation [13] . The exact relationship between β 2 -ARmediated anti-inflammatory effects and TLR signaling pathway remained to be elucidated in monocytes.
In the present study, we aimed to explore the underlying mechanism of the anti-inflammatory effects mediated by β 2 -AR stimulation in THP-1 cells. We first investigated if LPSinduced cytokines could be suppressed by fenoterol via ELISA assay. To confirm fenoterol' anti-inflammatory effect, downregulated LPS-induced membrane-bound TLR4/CD14 complex and CD14 level in THP-1 cells on stimulation of β 2 -AR were verified by flow cytometry. Then, we discovered that the total level of CD14 and TLR4 was not significantly changed by Western blotting, but interestingly, redistribution of CD14 and TLR4/CD14 complex mediated by β 2 -AR stimulation was found by confocal analysis. Lastly, anti-inflammatory effects and redistribution of CD14 and TLR4/CD14 complex mediated by β 2 -AR stimulation were abolished by siRNA-mediated knockdown of β-arrestin-2, which might play an important role in crosstalk of β 2 -AR and TLR [14] .
Materials and methods

Cell culture
The human monocytic cell line THP-1 (obtained from the cell center of Peking Union Medical College) was cultured in RPMI-1640 medium (Sigma Chemical Co, St Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 g/mL streptomycin at 37 °C in 5% CO 2 in a humidified incubator. Cells were centrifuged and resuspended with fresh medium at 10 6 /mL and incubated for another 24 h before use. The cells were washed and distributed into sterile microtiter plates at 10 6 /mL in RPMI-1640 medium containing 2% FBS stimulated with 0.1 µg/mL of Escherichia coli 0111:B4 LPS (Sigma) for 24 h (unless indicated otherwise) at 37 °C in the presence or absence of β 2 -AR agonists (fenoterol) and antagonists (ICI 118551) (both from Sigma). Downregulation (siRNA) of the β-arrestin-2 Cells were split at least 24 h prior to transfection and transfected with siRNA designed against β-arrestin-2 or control siRNA using the Oligofectamine™ transfection reagent (Invitrogen Life Technologies, Carlsbad, CA) according to the optimized procedure recommended by the producer as described elsewhere [15] . The siRNA sequence targeting β-arrestin-2 is 5' AAGGACCGCAAAGUGUUUGUG 3' (Shanghai GeneChem Co, Ltd, Shanghai,China). All assays were performed 72 h following transfection of siRNA. The inhibitory efficiency of siRNA probes was assessed by measuring knockdown of the β-arrestin-2 protein by Western blotting analysis.
ELISA assay
Concentrations of interleukin 8 (IL-8) and tumor necrosis factor α (TNF-α) from cell supernatants were determined by use of an ELISA system (R&D Systems, Minneapolis, MN) according to the manufacturer. The detection limits of ELISA for IL-8 and TNF-α were 10 pg/mL.
Flow cytometry
The expression of CD14 and TLR4/CD14 complex in THP-1 cells was determined by flow cytometry. After LPS stimulation in the presence or absence of fenoterol, the cells (10 6 / sample) were washed once with PBS, then incubated at 4 °C for 30 min with a combination of anti-CD14 FITC-conjugated (clone 61D3, 10 g/mL; eBioscience) and anti-TLR4 PE-conjugated antibodies (clone HTA125, 10 g/mL; eBioscience). After washing, cells were analyzed by use of a FACS Calibur (Becton Dickinson Biosciences, San José, CA, USA), and data were analyzed by use of the CELL QUEST Program (Becton Dickinson).
Western blotting and immunoprecipitation
After treatment, THP-1 cells were lysed in 10 mmol/L HEPES, pH 7.
Cell membrane proteins were prepared using the Plasma Membrane Protein Extraction Kit (Applygen Technologies Inc., Beijing, China). Cell membrane protein or cytoplasmic protein extracts, 60−90 µg were separated by 10% SDS-PAGE and electrotransferred onto anti-trocellulose membrane (BioRad, Hercules, CA, USA). TLR4, CD14, and β-arrestin-2 were detected with use of mouse monoclonal anti-human TLR4, CD14, and β-arrestin-2 antibody (Santa Cruz Biotechnology, Santa Cruz, CA), goat anti-mouse horseradish peroxidaseconjugated secondary antibody (Zhong Shan Jin Qiao Co, China), and enhanced chemiluminescence (Pierce Biotechnology). Band intensities were determined using computer program Image-J and were presented as the mean±SEM of the x-fold change over the respective control that was arbitrarily defined. For immunoprecipitation, 100 µg of membrane protein was incubated with 20 µL protein G plus-agarose (Santa Cruz Biotechnology, Santa Cruz, CA, USA) pre-equilibrated in lysis buffer and 10 µL of polyclonal antibodies for 4 h at 4 °C. Samples were then centrifuged for 10 s, and the pellets were washed three times with 1 mL of lysis buffer. Bound proteins were eluted by the addition of 15 µL of SDS sample buffer and boiling for 5 min and then analyzed by SDS-PAGE and immunoblotting.
Confocal analysis
A standard immunocytoplasmic staining protocol was used [16] . Briefly, after LPS stimulation in the presence or absence of fenoterol and siRNA-mediated knockdown of β-arrestin-2, THP-1 cells were cultured in a chamber slide (Zhong Shan Jin Qiao Co, China) for 20 min, then fixed with ice-cold acetone for 20 min and stained with PE-conjugated monoclonal antibodies for mouse anti-human TLR4 (HTA125) and FITCconjugated monoclonal antibodies for mouse anti-human CD14 (61D3) for 24 h at room temperature, then washed with 
Statistical analysis
Experiments were repeated at least three times. Data are presented as mean±SEM. The statistical significance of the differences between the means of the groups was determined by one-way ANOVA followed by Bonferroni post-hoc test. P values of <0.05 were considered statistically significant. Fenoterol down-regulates membrane-bound TLR4/CD14 complex and CD14 in THP-1 cells After LPS (0.1 µg/mL) stimulation for 24 h, the effect of fenoterol (10 -6 mol/L) on change of the membrane-bound TLR4/ CD14 complex and CD14 levels in THP-1 cells was examined by flow cytometry. Although LPS-induced TLR4 expression was not significantly changed with β 2 -AR stimulation (data not shown), the membrane-bound TLR4/CD14 complex and CD14 levels in THP-1 cells were significantly decreased on incubation with fenoterol, pre-incubation with ICI118551 for 30 min abolished the effect of down-regulation of TLR4/CD14 complex and CD14 mediated by fenoterol (Figure 2A) . Similar results were found by Western blotting ( Figure 2B ). (Figure 3Aa, 3Ad) . However, confocal microscopy revealed that the membrane-bound TLR4/ CD14 complex was reduced in level with pre-incubation of fenoterol (10 -6 mol/L) (Figure 3Bb ) in LPS-stimulated THP-1 cells (Figure 3Ba ) and redistribution of TLR4/CD14 complex under stimulation with β 2 -AR was abolished with preincubation of ICI118551 for 30 min (Figure 3Bc) . Meanwhile, membrane-bound β-arrestin-2 was increased by treatment with fenoterol (10 -6 mol/L) for 3 min ( Figure 3C ).
Results
Fenoterol inhibits LPS
Silencing β-arrestin-2 abolished the anti-inflammatory effects and redistribution of LPS-induced TLR4/CD14 complex stimulated by β 2 -AR The siRNA used almost abrogated β-arrestin-2 expression in THP-1 cells ( Figure 4A ). To determine whether the β-arrestin-2 siRNA could affect anti-inflammatory effects and redistribution of LPS-stimulated TLR4/CD14 complex on stimulation with β 2 -AR, afer transfection with siRNA designed against β-arrestin-2 or control siRNA, THP-1 cells were stimulated with LPS in the presence or absence of fenoterol as described before. As shown in ( Figure 4B, 4C) , anti-inflammatory effects and redistribution of CD14 and TLR4/CD14 complex mediated by β 2 -AR stimulation were abolished by siRNAmediated knockdown of β-arrestin-2, while not abolished by control siRNA (data not shown).
Discussion
LPS-induced inflammatory response was abolished in mice deficient in MyD88
-/-, an important downstream signaling molecule of TLRs, suggesting that TLRs play a central role in the pathogenic microorganism-mediated inflammatory response [13, 17] . On the other hand, we noticed that β 2 -AR signaling exerted anti-inflammatory effect [6, 7] . Therefore, further To understand the mechanism of β 2 -AR-mediated TLR regulation, TLR binding structure and its co-factors first need to be considered. All TLRs are type I transmembrane receptors, characteristic of a highly variable extracellular region, including a leucine-rich repeat domain involved in ligand binding and an intracellular tail containing a highly conserved region, the Toll/Interleukin-1 Receptor (TIR) homology domain, which mediates interaction between TLRs and downstream signaling molecules [13] . Activation of TLR4 is initiated as follows: the binding of the LPS binding protein (LBP)/LPS complex to membrane CD14 (mCD14), then binding and forming the TLR4/CD14 complex and activating TLR4, which activates signal transduction pathways and induces inflammatory Acta Pharmacologica Sinica npg gene expression [13] . Thus, we speculated that a change in the membrane-bound TLR4/CD14 complex level might affect the activation of TLR4. Furthermore, in the present study, we identified that reduced inflammatory response mediated by β 2 -AR stimulation was related to the change of membranebound TLR4/CD14 complex (Figure 2 ) but not total protein expression of TLR4 in monocytes ( Figure 3A) . Interestingly, despite no significant change in total protein expression of TLR4 with β 2 -AR stimulation, confocal microscopy revealed redistribution of the TLR4/CD14 complex ( Figure 3B) . A previous study showed that human corneal epithelial cells express TLR2 and TLR4 intracellularly but not at the cell surface and fails to respond to LPS even on artificial translocation of LPS [18] . Thus, membrane-bound TLRs play a central role in LPS-induced inflammatory response, and β 2 -AR mediated reduction of membrane-bound TLRs was responsible for the reduced inflammatory response in monocytes.
Whether the β 2 -AR-mediated anti-inflammatory effect depends on the inhibition of the receptor level or downstream signaling of TLRs is still in debate. There have been some reports that the anti-inflammatory effect of β-receptor activation was associated with a change in content of IκB/ NF-κB, extracellular signal-regulated kinase 1/2 (ERK1/2) or p38 [6, 19] , whether these changes were the direct effect of A recent study revealed that β 2 -AR agonist exerts its anti-inflammatory effect through inhibiting the expression of membrane-bound CD14, a co-factor of TLRs, on monocytes [7] . The regulation of TLRs might be a potential target of the β 2 -AR agonist. Our results further demonstrated that the reduced level of membrane-bound TLRs was responsible for the anti-inflammatory effect of β 2 -AR agonist ( Figure 2 ). As well, the decreased activation of NF-κB signaling was attributed to the down-regulation of membranebound TLRs. Whether the signaling of TLRs is a specific pathway for the β 2 -AR-mediated anti-inflammatory effect still needs to be elucidated.
Upon agonist binding, β-arrestins1/2 is recruited to the plasma membrane and mediates desensitization and internalization of G-protein-coupled receptor (GPCR) [20] . However, β-arrestins have been considered as novel non-G proteindependent signaling molecules and play functional roles in the regulation of a variety of signaling pathways and in the mediation of cross-talk between receptors [21] [22] [23] . For example, β-arrestin-2-dependent stabilization of cytosolic IκBα and inhibition of NF-κB activation following LPS stimulation are essential for rapid and sufficient production of NO in response to microbial attack [14] . Moreover, there is accumulating evidence that β-arrestin-2, which is expressed abundantly in the spleen, is functionally involved in some important immune responses, such as regulation of lymphocyte chemotaxis and homing [24, 25] . In the present study we used RNA interference against β-arrestin-2 to test its role in anti-inflammatory effects stimulated by β 2 -AR. The specificity and efficiency of siRNA against β-arrestin-2 was demonstrated by Western blotting ( Figure 4A ). The translocation of β-arrestins1/2 to the plasma membrane was reported to interact directly with two structural components of clathrin-coated pits, clathrin and AP-2, promoting the endocytosis of β 2 -AR into early endosomes via clathrin-coated vesicles [9, 10] . Moreover, TLR4 was also endocytosed by a dynamin and clathrin dependent mechanism and colocalized with LPS into early/sorting endosomes [11] . Therefore, we hypothesized that β-arrestins' translocation to the cell surface was associated with redistribution of TLRs on stimulation of β 2 -AR. Meanwhile, fenoterol increased membranebound β-arrestin-2 expression, suggesting that β-arrestin-2 translocated to the cell surface on stimulation of β 2 -AR in THP-1 cells ( Figure 3C ). Our study indicated that depletion of β-arrestin-2 abolished redistribution of CD14 and TLR4/ CD14 complex mediated by β 2 -AR activation ( Figure 4B ), suggesting that β-arrestin-2' translocation and β-arrestin-2/ clathrin-dependent redistribution of TLRs was required for anti-inflammatory effects stimulated by β 2 -AR. Further study needs to clarify β-arrestin-2/clathrin mediated redistribution of TLRs on stimulation of β 2 -AR.
Taken together, we provided evidence that β 2 -AR agonist exerts anti-inflammatory effects by down-regulating membrane-bound TLRs through β-arrestin-2. Down-regulation npg of β-arrestin-2 significantly attenuates the anti-inflammatory effects mediated by fenoterol, suggesting that β-arrestin-2 is beneficial to protecting organism against invading pathogens. This finding has implications not only with regard to our understanding of molecular mechanism for the β 2 -AR agonists' anti-inflammatory effects but also for the development of therapeutic agents targeting these pathways, which may be helpful for treatment of acute and chronic inflammatory diseases.
